VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the long-term safety of VAXZEVRIA

Study identifier:D8111C00005

ClinicalTrials.gov identifier:NCT05135455

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

VAXZEVRIA Intramuscular injection General use result study for the long-term safety of VAXZEVRIA

Medical condition

Prevention of infectious disease caused by SARS-CoV-2

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

467

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 21 Apr 2022
Primary Completion Date: 31 Aug 2023
Study Completion Date: 31 Aug 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria